Product Code: ETC7215413 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview |
3.1 France Country Macro Economic Indicators |
3.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, 2021 & 2031F |
3.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Industry Life Cycle |
3.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Porter's Five Forces |
3.5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.7 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) in France |
4.2.2 Advances in medical research leading to improved diagnosis and treatment options |
4.2.3 Growing awareness among healthcare professionals and patients about CIDP |
4.3 Market Restraints |
4.3.1 High cost of CIDP treatments and therapies |
4.3.2 Limited availability of specialized healthcare facilities for CIDP patients in France |
5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends |
6 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Types |
6.1 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous Immunoglobulin, 2021- 2031F |
6.1.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.1.5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Plasmapheresis, 2021- 2031F |
6.1.6 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Physiotherapy, 2021- 2031F |
6.1.7 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Diagnosis |
6.2.1 Overview and Analysis |
6.2.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Electrodiagnostic Testing, 2021- 2031F |
6.2.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Nerve Conduction, 2021- 2031F |
6.2.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By EMG, 2021- 2031F |
6.2.5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Spinal Fluid Analysis, 2021- 2031F |
6.2.6 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.3.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.5.5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
7 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Import-Export Trade Statistics |
7.1 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Export to Major Countries |
7.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Imports from Major Countries |
8 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Key Performance Indicators |
8.1 Average time from symptom onset to CIDP diagnosis |
8.2 Patient adherence to CIDP treatment regimens |
8.3 Number of clinical trials focused on CIDP therapies in France |
8.4 Rate of adoption of new CIDP treatment guidelines by healthcare providers |
8.5 Level of patient satisfaction with CIDP management and care services |
9 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Opportunity Assessment |
9.1 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Competitive Landscape |
10.1 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue Share, By Companies, 2024 |
10.2 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |